Back to Search

A Phase1, First-in-Human, Open-Label, Dose Escalation and Expansion Study of CUE-101 Monotherapy in Second Line or CUE-101 Combination Therapy With Pembrolizumab in First Line Patients With HPV16+ Recurrent/Metastatic HNSCC KEYNOTE-A78

  • Protocol Number: 201905108
  • Principal Investigator: Adkins, Douglas
  • Cancer Types: Head & Neck

For more information on this trial, contact us here:


Brief Summary

Protocol Interventions